Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOOKAD Soluble versus active surveillance for localized low-risk prostate cancer
NL-OMON41452Phase 3Active, not recruiting
- Sponsor
- Steba Biotech
- Start
- Aug 2011
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of talaporfin sodium in prostate cancer (PCa) (2 arms), sponsored by Steba Biotech. Primary endpoints: Co-primary endpoint A: absence of definite cancer and Co-primary endpoint B: treatment failure due to progression. Started Aug 2011; status: active, not recruiting.
02
Drugs
talaporfin sodium
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON41452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41452.